We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie
Read MoreHide Full Article
For Immediate Release
Chicago, IL – December 1, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Avidity Biosciences, Inc. (RNA - Free Report) , Bristol Myers Squibb (BMY - Free Report) , Vertex Pharmaceuticals Inc. (VRTX - Free Report) , Arcturus Therapeutics (ARCT - Free Report) and BioVie Inc. (BIVI - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Biotech Stock Roundup: Deal Expansions, Setbacks & More
The focus is back on regular drug approvals and other pipeline and regulatory updates in the biotech sector. Quite a few other companies offered important updates on their key candidates.
Recap of the Week’s Most Important Stories:
RNA Surges on Deal Expansion: Shares of Avidity Biosciences, Inc. soared 14.9% following the expansion of its global licensing and research collaboration with biotech giant Bristol Myers Squibb.
Avidity announced a research collaboration with MyoKardia in 2021 to demonstrate the potential utility of antibody oligonucleotide conjugates (AOCs) in cardiac tissue. MyoKardia was acquired by Bristol Myers in 2020.
The expanded collaboration will focus on the discovery, development and commercialization of up to five cardiovascular targets leveraging Avidity's proprietary AOC platform technology, with potential cumulative payments of up to $2.3 billion.
Per the terms of the agreement, Bristol Myers will make an upfront cash payment of $60 million to Avidity. BMY will also purchase approximately $40 million of Avidity’s common stock at a price of $7.88 per share.
In addition, Avidity is entitled to receive up to approximately $1.35 billion in research and development milestone payments, up to roughly $825 million in commercial milestone payments and tiered royalties up to low double-digits on net sales. Any expenses related to clinical development, regulatory and commercialization activities arising from this collaboration will also be funded by Bristol Myers. The infusion of cash by bigwig BMY boosted investor sentiment, leading to the rise in share price.
Regulatory Updates From Vertex: Vertex Pharmaceuticals Inc. announced that the European Medicines Agency has validated a type II variation application to the marketing authorization for blockbuster cystic fibrosis (CF) medicine, Kaftrio.
The application seeks an expansion of the approved indication for Kaftrio in a combination regimen with Kalydeco (ivacaftor) for the treatment of people with CF aged two and above who have a mutation in the cystic fibrosis transmembrane conductance regulator gene that is responsive based on clinical and/or in vitro data, including the N1303K mutation. The Committee for Medicinal Products for Human Use will now review the application and issue an opinion to the European Commission (“EC”) on the same.
A day before, VRTX obtained the EC’s approval for the label expansion of Kaftrio for treating children two to five years old. The EC approved Kaftrio in combination with Kalydeco for treating CF in children who have at least one F508del mutation in the CF transmembrane conductance regulator gene. The drug is already approved in the EU for the same indication in patients aged six years and older.
Updates From Arcturus: Arcturus Therapeutics announced that the FDA has granted orphan drug designation for the company’s product candidate ARCT-032 to treat CF. The FDA grants the designation to support the development of medicines for rare disorders that affect fewer than 200,000 patients in the United States. Shares were up on the news.
The designation will give Arcturus market exclusivity for ARCT-032 for a predefined period in the CF indication, along with the exemption of FDA application fees and tax credits for qualified clinical studies, all subject to approval. Arcturus said that the first CF patient in its early-stage study of ARCT-032 has successfully completed two administrations of the investigational drug candidate. The company is on track to share interim results from the phase Ib study in the first half of 2024.
BioVie Down on Study Results: BioVie Inc. announced a positive analysis of top-line efficacy data from its phase III study of its investigational candidate, NE3107, in the treatment of mild to moderate Alzheimer’s Disease (AD). The advantage of treating AD patients with NE3107 compared to placebo in the late-stage study demonstrated a benefit equal to or greater than that offered by currently approved monoclonal antibodies in the treatment of AD without the associated safety concerns. BioVie reported that NE3107-treated patients experienced an age deceleration advantage by 4.66 months to a year compared to placebo, as measured by epigenetics/DNA methylation Skin Blood Clock.
However, the stock declined due to investors’ skepticism regarding the results announced, fueled by significant study conduct violations and protocol deviations reported by the company. The phase III study of NE3107, initiated during the COVID-19 pandemic, enrolled a total of 439 AD patients. After completion of the study, BioVie observed significant deviation from protocol and good clinical practice violations in several study sites.
Based on this development, BioVie decided to exclude all patients treated with the candidate in these study sites from the analysis of study efficacy data. BioVie also reported that due to the exclusions made from the initial patient population, the primary efficacy endpoint of the study missed achieving statistical significance.
Performance
The Nasdaq Biotechnology Index has gained 0.49% in the past four trading sessions. Among the biotech giants, Regeneron has gained 1.11% during the period. Over the past six months, shares of Moderna have plunged 38.70%. (See the last biotech stock roundup here: Biotech Stock Roundup: BMY, TSVT Down on Setback, TRDA, MOR Offer Updates).
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie
For Immediate Release
Chicago, IL – December 1, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Avidity Biosciences, Inc. (RNA - Free Report) , Bristol Myers Squibb (BMY - Free Report) , Vertex Pharmaceuticals Inc. (VRTX - Free Report) , Arcturus Therapeutics (ARCT - Free Report) and BioVie Inc. (BIVI - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Biotech Stock Roundup: Deal Expansions, Setbacks & More
The focus is back on regular drug approvals and other pipeline and regulatory updates in the biotech sector. Quite a few other companies offered important updates on their key candidates.
Recap of the Week’s Most Important Stories:
RNA Surges on Deal Expansion: Shares of Avidity Biosciences, Inc. soared 14.9% following the expansion of its global licensing and research collaboration with biotech giant Bristol Myers Squibb.
Avidity announced a research collaboration with MyoKardia in 2021 to demonstrate the potential utility of antibody oligonucleotide conjugates (AOCs) in cardiac tissue. MyoKardia was acquired by Bristol Myers in 2020.
The expanded collaboration will focus on the discovery, development and commercialization of up to five cardiovascular targets leveraging Avidity's proprietary AOC platform technology, with potential cumulative payments of up to $2.3 billion.
Per the terms of the agreement, Bristol Myers will make an upfront cash payment of $60 million to Avidity. BMY will also purchase approximately $40 million of Avidity’s common stock at a price of $7.88 per share.
In addition, Avidity is entitled to receive up to approximately $1.35 billion in research and development milestone payments, up to roughly $825 million in commercial milestone payments and tiered royalties up to low double-digits on net sales. Any expenses related to clinical development, regulatory and commercialization activities arising from this collaboration will also be funded by Bristol Myers. The infusion of cash by bigwig BMY boosted investor sentiment, leading to the rise in share price.
Avidity currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Regulatory Updates From Vertex: Vertex Pharmaceuticals Inc. announced that the European Medicines Agency has validated a type II variation application to the marketing authorization for blockbuster cystic fibrosis (CF) medicine, Kaftrio.
The application seeks an expansion of the approved indication for Kaftrio in a combination regimen with Kalydeco (ivacaftor) for the treatment of people with CF aged two and above who have a mutation in the cystic fibrosis transmembrane conductance regulator gene that is responsive based on clinical and/or in vitro data, including the N1303K mutation. The Committee for Medicinal Products for Human Use will now review the application and issue an opinion to the European Commission (“EC”) on the same.
A day before, VRTX obtained the EC’s approval for the label expansion of Kaftrio for treating children two to five years old. The EC approved Kaftrio in combination with Kalydeco for treating CF in children who have at least one F508del mutation in the CF transmembrane conductance regulator gene. The drug is already approved in the EU for the same indication in patients aged six years and older.
Updates From Arcturus: Arcturus Therapeutics announced that the FDA has granted orphan drug designation for the company’s product candidate ARCT-032 to treat CF. The FDA grants the designation to support the development of medicines for rare disorders that affect fewer than 200,000 patients in the United States. Shares were up on the news.
The designation will give Arcturus market exclusivity for ARCT-032 for a predefined period in the CF indication, along with the exemption of FDA application fees and tax credits for qualified clinical studies, all subject to approval. Arcturus said that the first CF patient in its early-stage study of ARCT-032 has successfully completed two administrations of the investigational drug candidate. The company is on track to share interim results from the phase Ib study in the first half of 2024.
BioVie Down on Study Results: BioVie Inc. announced a positive analysis of top-line efficacy data from its phase III study of its investigational candidate, NE3107, in the treatment of mild to moderate Alzheimer’s Disease (AD). The advantage of treating AD patients with NE3107 compared to placebo in the late-stage study demonstrated a benefit equal to or greater than that offered by currently approved monoclonal antibodies in the treatment of AD without the associated safety concerns. BioVie reported that NE3107-treated patients experienced an age deceleration advantage by 4.66 months to a year compared to placebo, as measured by epigenetics/DNA methylation Skin Blood Clock.
However, the stock declined due to investors’ skepticism regarding the results announced, fueled by significant study conduct violations and protocol deviations reported by the company. The phase III study of NE3107, initiated during the COVID-19 pandemic, enrolled a total of 439 AD patients. After completion of the study, BioVie observed significant deviation from protocol and good clinical practice violations in several study sites.
Based on this development, BioVie decided to exclude all patients treated with the candidate in these study sites from the analysis of study efficacy data. BioVie also reported that due to the exclusions made from the initial patient population, the primary efficacy endpoint of the study missed achieving statistical significance.
Performance
The Nasdaq Biotechnology Index has gained 0.49% in the past four trading sessions. Among the biotech giants, Regeneron has gained 1.11% during the period. Over the past six months, shares of Moderna have plunged 38.70%. (See the last biotech stock roundup here: Biotech Stock Roundup: BMY, TSVT Down on Setback, TRDA, MOR Offer Updates).
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.